1. Home
  2. AMGN
Logo Amgen Inc.

AMGN

Amgen Inc.

as 05-24-2024 4:00pm EST

$
-
-
-
.
-
-
-
$
-
.
-
-
-
-
.
-
-
%

Health Care

Biotechnology: Biological Products (No Diagnostic Substances)

Nasdaq

Amgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). The 2023 Horizon acquisition brings several rare-disease drugs, including thyroid eye disease drug Tepezza. Amgen also has a growing biosimilar portfolio.

Founded: 1980 Country:
United States
United States
Employees: N/A City: THOUSAND OAKS
Market Cap: 164.4B IPO Year: N/A
Target Price: $304.89 AVG Volume (30 days): 2.7M
Analyst Decision: Buy Number of Analysts: 21
Dividend Yield: 2.94% Dividend Payout Frequency: Quarterly
EPS: 7.01 EPS Growth: -52.35
52 Week Low/High: $211.71 - $329.72 Next Earning Date: 05-02-2024
Revenue: $29,532,000,000 Revenue Growth: 12.76%
Revenue Growth (this year): 19.4% Revenue Growth (next year): 2.84%

AMGN Daily Stock ML Predictions

Stock Insider Trading Activity of Amgen Inc. (AMGN)

Name Ticker Relationship Date Transaction Cost Per Share Shares Total Value Securities Owned After Transaction(s) SEC Form 4
Grygiel Nancy A. AMGN SVP & CCO May 3 '24 Sell $313.09 2,117 $662,801.58 9,883 SEC Form 4
Graham Jonathan P AMGN EVP, Gen. Counsel & Secy. Nov 8 '23 Sell $272.81 10,000 $2,728,136.00 28,078 SEC Form 4

Share on Social Networks: